Literature DB >> 22328501

Stepwise androgen receptor dimerization.

Martin E van Royen1, Wiggert A van Cappellen, Carola de Vos, Adriaan B Houtsmuller, Jan Trapman.   

Abstract

Androgen-regulated gene expression is a highly coordinated dynamic process mediated by androgen receptor (AR) ligand binding and DNA binding, and by specific AR protein-protein interactions. The latter include DNA-binding domain (D-box) interactions in AR homodimers, and the interaction of the FQNLF motif in the AR N-terminal domain and the coactivator groove in the ligand-binding domain (N/C interaction). We have studied these interactions in AR homodimerization using quantitative imaging techniques. We found that the initial cytoplasmic intramolecular AR N/C interaction after ligand binding is followed by a D-box-dimerization-dependent transition to intermolecular N/C interaction in a proportion of nuclear ARs. The consecutive steps leading to homodimerization are initiated prior to DNA binding. Our data indicate the presence of nuclear pools of both AR homodimers and monomers. On the basis of AR-regulated reporter assays we propose specificity in regulation of gene expression by AR homodimers and monomers mediated by AR domain interactions. Moreover, our findings elucidate important steps in the spatiotemporal organization of AR intra- and inter-molecular interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22328501     DOI: 10.1242/jcs.096792

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  57 in total

1.  Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

Authors:  Bo Li; Wenfu Lu; Zhenbang Chen
Journal:  Receptors Clin Investig       Date:  2014

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

Review 3.  Role of androgen receptor splice variants, their clinical relevance and treatment options.

Authors:  S Wach; H Taubert; M Cronauer
Journal:  World J Urol       Date:  2019-01-19       Impact factor: 4.226

4.  Identification and Characterization of the Androgen Receptor From the American Alligator, Alligator mississippiensis.

Authors:  Shinichi Miyagawa; Ryohei Yatsu; Satomi Kohno; Brenna M Doheny; Yukiko Ogino; Hiroshi Ishibashi; Yoshinao Katsu; Yasuhiko Ohta; Louis J Guillette; Taisen Iguchi
Journal:  Endocrinology       Date:  2015-05-14       Impact factor: 4.736

5.  Interaction of the phosphorylated DNA-binding domain in nuclear receptor CAR with its ligand-binding domain regulates CAR activation.

Authors:  Ryota Shizu; Jungki Min; Mack Sobhany; Lars C Pedersen; Shingo Mutoh; Masahiko Negishi
Journal:  J Biol Chem       Date:  2017-11-13       Impact factor: 5.157

Review 6.  [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Authors:  M C Hupe; A Offermann; F Perabo; C Chandhasin; S Perner; A S Merseburger; M V Cronauer
Journal:  Urologe A       Date:  2018-02       Impact factor: 0.639

Review 7.  Emerging data on androgen receptor splice variants in prostate cancer.

Authors:  Subing Cao; Yang Zhan; Yan Dong
Journal:  Endocr Relat Cancer       Date:  2016-10-04       Impact factor: 5.678

8.  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Authors:  Kush Dalal; Mani Roshan-Moniri; Aishwariya Sharma; Huifang Li; Fuqiang Ban; Mohamed Hessein; Michael Hsing; Kriti Singh; Eric LeBlanc; Scott Dehm; Emma S Tomlinson Guns; Artem Cherkasov; Paul S Rennie
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

Review 9.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Authors:  E S Antonarakis; A J Armstrong; S M Dehm; J Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

Review 10.  Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Authors:  D J Crona; M I Milowsky; Y E Whang
Journal:  Clin Pharmacol Ther       Date:  2015-10-01       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.